KGX-101

N/A

Report date: 2024/10/12 14:22:44

Base Information

Drug NameKGX-101
Drug Alias Name肿瘤特异性重组IL-12 Fc融合蛋白KGX-101KGX101KGX-101(IL-12-Fc融合蛋白)KGX-101(改造优化的细胞因子IL12前药分子)
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein
Mechanisms of ActionInterleukin-12 replacements
TargetsInterleukin-12
Therapy Area/IndicationsSolid tumoursNeoplasm MetastasisNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustraliaMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShanghai KangaBio Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesKangabio Australia Ltd PtyKangaBioShanghai KangaBio Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursNeoplasm Metastasis
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A